Introduction
Arrowhead Pharmaceuticals, Inc. has developed a drug that treats intractable diseases by inhibiting the genes that cause them, thus silencing the genes. Arrowhead therapy utilizes a wide range of RNA chemicals and efficient delivery methods to trigger RNA interference mechanisms, inducing rapid, deep, and durable knockout of target genes. RNA interference (RNAi) is a mechanism present in living cells that inhibits the expression of specific genes, thereby affecting the production of specific proteins. RNAi is considered one of the most important recent discoveries in life sciences, with the potential to revolutionize medicine. The discoverers of RNAi were awarded the Nobel Prize in 2006 for their work. Arrowhead Pharmaceuticals, Inc.'s RNAi-based therapy utilizes this natural pathway of gene silencing.
